Xenetic Biosciences (XBIO) Profit After Tax (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Profit After Tax came in at -$456382.0 in Q1 2026, up 49.47% YoY from -$305339.1 in Q1 2025, and up 21.19% on a QoQ basis from -$579076.0 in Q4 2025.
Xenetic Biosciences (XBIO) Profit After Tax (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Profit After Tax data on file, last reported at -$456382.0 in Q1 2026.
- Quarterly Profit After Tax rose 49.47% year-over-year to -$456382.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.2 million (up 39.1% YoY) and the FY2025 annual result came in at -$2.7 million, up 32.31% from the prior year.
- Profit After Tax grew to -$456382.0 in Q1 2026, from -$579076.0 in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$436671.0 in Q3 2024 to a low of -$2.7 million in Q2 2022.
- A 5-year average of -$1.0 million and a median of -$1.1 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax tumbled 141.46% — and 2023, when it soared 60.67%.
- Tracing XBIO's Profit After Tax over 5 years: stood at -$1.5 million in 2022, then climbed by 20.98% to -$1.2 million in 2023, then increased by 9.99% to -$1.1 million in 2024, then jumped by 45.09% to -$579076.0 in 2025, then grew by 21.19% to -$456382.0 in 2026.
- The last three Profit After Tax figures came in at -$456382.0 (Q1 2026), -$579076.0 (Q4 2025), and -$509940.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | -929,695.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -929,695.00 |
| Mar 31, 2026 | -456,382.00 |
| Dec 31, 2025 | -579,076.00 |
| Sep 30, 2025 | -509,940.00 |
| Jun 30, 2025 | -688,703.00 |
| Mar 31, 2025 | -903,141.00 |
| Dec 31, 2024 | -1.05 Mn |
| Sep 30, 2024 | -436,671.00 |
| Jun 30, 2024 | -1.27 Mn |
| Mar 31, 2024 | -1.20 Mn |
| Dec 31, 2023 | -1.17 Mn |
| Sep 30, 2023 | -1.06 Mn |
| Jun 30, 2023 | -1.05 Mn |
| Mar 31, 2023 | -856,554.00 |
| Dec 31, 2022 | -1.48 Mn |
| Sep 30, 2022 | -804,017.00 |
| Jun 30, 2022 | -2.67 Mn |
| Mar 31, 2022 | -1.59 Mn |
| Dec 31, 2021 | -1.84 Mn |
| Sep 30, 2021 | -1.35 Mn |